Publikationer

Filter
Poster
2017

Adenoviruses armed with TNFa and IL-2 increase efficacy of adoptive cell therapy even in the absence of preparative lymphodepleting conditioning

Santos, J. M., Havunen, R. S. A., Cervera-Carrascon, V., Siurala, M. O., Sorsa, S., Anttila, M. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Adenoviruses armed with TNFα and IL-2 succesfully enable adoptive T-cell therapy in solid tumors.

Sorsa, S., Siurala, M. O., Havunen, R. S. A., Santos, J. M., Cervera-Carrascon, V. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Adenoviruses coding for TNFa and IL-2 for the replacement of lymphodepleting preconditioning in adoptive cell therapy

Santos, J. M., Havunen, R. S. A., Cervera-Carrascon, V., Siurala, M. O., Sorsa, S., Anttila, M. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

CD40L coding oncolytic adenovirus 3 is a potent facilitator of dendritic cell therapy.

Zafar, S., Siurala, M. O., Sorsa, S., Hemminki, O. J., Havunen, R. S. A., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A-M. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Cytokine-armed oncolytic adenovirus enables system-wide antitumor efficacy – the abscopal effect - following local treatment

Havunen, R. S. A., Cervera-Carrascon, V., Santos, J. M., Sorsa, S. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Delivering complete responses against solid tumors by checkpoint blockade enabled with TNFa and IL-2 armed adenoviruses

Cervera-Carrascon, V., Siurala, M. O., Santos, J. M., Havunen, R. S. A., Sorsa, S. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Enabling Immune checkpoint blockade with oncolytic viruses armed with TNFa and IL-2.

Cervera-Carrascon, V., Siurala, M. O., Santos, J. M., Havunen, R. S. A., Sorsa, S. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Interleukin 8 activity influences the efficacy of adenoviral immunotherapy in cancer patients.

Taipale, A. V. K., Tähtinen, S., Siurala, M. O., Havunen, R. S. A., Koski-Palkén, A. K. E., Liikanen, I. J., Pakarinen, P., Koivisto-Korander, R., Kankainen, M. J., Joensuu, T. K., Kanerva, A-M. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Preclinical studies of oncolytic adenovirus 3 coding for CD40L as an enabler of dendritic cell therapy.

Zafar, S., Siurala, M. O., Sorsa, S., Hemminki, O. J., Havunen, R. S. A., Tähtinen, S., Bramante, S., Vassilev, L., Wang, H., Lieber, A., Hemmi, S., de Gruijl, T., Kanerva, A-M. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

Systemic antitumor effects achieved with adoptive cell therapy-enabling armed oncolytic adenoviruses

Havunen, R. S. A., Santos, J. M., Sorsa, S., Cervera-Carrascon, V., Siurala, M. O. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster

T-cell therapy –enabling oncolytic adenoviruses for the treatment of melanoma.

Santos, J. M., Siurala, M. O., Havunen, R. S. A., Cervera-Carrascon, V., Sorsa, S. & Hemminki, A. E., 2017.

Forskningsoutput: KonferensbidragPoster